Oracle Life Sciences CancerMPact® (USA)

Database Contact Data

Stephanie Hawthorne
Oracle Life Sciences 
Email: stephanie.hawthorne@oracle.com

Alternate Contact

1. Haris Vikis
Oracle Life Sciences 
Email: haris.vikis@oracle.com

2. If you cannot reach the database manager, you may contact the company by completing the contact form at: cancermpact_support_grp@oracle.com

References of Studies Using/Describing Database

1. Clark O, Sarmento T, Eccleston A, Brinkmann J, Picoli R, Daliparthi V, Voss J, Chandrasekar S, Thompson A, Chang J.  Economic Impact of Bladder Cancer in the USA. Pharmacoecon Open. 2024 Nov;8(6):837-845.

2. Durbin L, Murali B, Li S, Hawthorne S, Clark O. Treatment patterns in advanced/metastatic non-small-cell lung cancer in China: results from the CancerMPact() survey 2021. Future Oncol. 2024;20(19):1319-1331.

3. Zhu X, Durbin L, Kanas G, Phiri K, Keeven K, Clark O, Nersesyan K, Aziez A, Stojadinovic A, Bell KF. Metastatic non-small-cell lung cancer without driver mutations: projections by therapy line in Western Europe, 2021-2026. Future Oncol. 2023 Oct;19(33):2237-2250.

4. A Bueno AP, Clark O, Turnure M, Moreira ES, Yuasa A, Sugiyama S, Kirker M, Li S, Hou N, Chang J, Kearney M, Kanas G. Treatment patterns in metastatic bladder cancer in Japan: results of the CancerMPact() survey 2020. Future Oncol. 2024 Mar;20(10):603-611.

5. Murali B, Durbin L, Vijaykumar S, Yang L, Li S, Zhao L, Hawthorne S, Kanas G, Davis C, Clark O. Treatment of HR+/HER2- breast cancer in urban mainland China: results from the CancerMPact Survey 2019. Breast Cancer Res Treat. 2022 Oct;195(3):441-451.

6. de Sá Moreira E, Robinson D, Hawthorne S, Zhao L, Hanson M, Kanas G, Turnure M, Davis C, Clark O. Patterns of Care and Outcomes for Non-Metastatic Prostate Cancer in the United States: Results of the CancerMPact® Survey 2018. Cancer Manag Res. 2021 Dec 11;13:9127-9137.

7. Kanas G, Ge W, Quek RG, Keeven K, Nersesyan K, Arnason JE. Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020–2025. Leukemia & Lymphoma. 2021 Oct 4:1-0.

8. Ge W, Arnason JE, Quek RG, Keeven K, Nersesyan K, Kanas G. EPR21-034: Epidemiology of Diffuse Large B Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) Patients by Line of Therapy in the United States (US) and Europe (EU). Journal of the National Comprehensive Cancer Network. 2021 Mar 17;19(3.5):EPR21-034.

9. Kanas G, Clark O, Keeven K, Nersesyan K, Sansbury L, Hogea C. Estimate of multiple myeloma patients by line of therapy in the USA: population-level projections 2020–2025. Future Oncology. 2021 Feb;17(8):921-30.

10. Kanas G, Clark O, Keeven K, Nersesyan K, Sansbury L, Hoggea C. Population-Level Projections for Multiple Myeloma Patients By Line of Therapy in the USA. Blood. 2020 Nov 5;136:2-3.

2/13/18: Nine new oncology profiles from IQVIA

IQVIA Oncology Dynamics, formerly QuintilesIMS Oncology Dynamics, is a market research tool that has been designed to monitor various cancer treatments and therapies. It segments patients by indication, stage, and line of therapy to provide an understanding of patient pathways, prescribers, products, prescribing initiation and treatment practice patterns.

The full portfolio is a global database comprising patient records spanning nine (9) countries; each country has a separate profile in our resource.

Subscribe to